ReviewPharmacoEconomics2022
Economic Implications of Endometriosis: A Review.
Review in PharmacoEconomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Blood-invigorating Chinese herbal medicines plus conventional therapy for endometriosis: a network meta-analysis of 107 randomized controlled trials.Frontiers in medicine · 2026Pooled it
- Understanding the impact of endometriosis on women's life: an integrative review of systematic reviews.BMC women's health · 2024Pooled it
- Trial
- Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT.Health technology assessment (Winchester, England) · 2024Trial
- Gut Dysbiosis in Selected Gynecological Diseases Associated with Female Infertility: A Scoping Review.Journal of clinical medicine · 2026Review
- Radiomics and Artificial Intelligence in Ovarian Endometriosis Imaging: A Systematic Review and Critical Appraisal of Emerging Evidence.Bioengineering (Basel, Switzerland) · 2026Review
- Global RNA expression analysis of patient samples identified potential diagnostic biomarkers specific for peritoneal, ovarian and deep endometriosis.Scientific reports · 2026Article
- Bidirectional Associations Between Circulating Polyunsaturated Fatty Acids and Female Reproductive Endocrine-Related Diseases: A Mendelian Randomization Study.International journal of women's health · 2026Article
- Analysis of Acupoint Selection and Combinations in Acupuncture Treatment of Endometriosis: A Protocol for Data Mining.Journal of pain research · 2026Article
- Genetically predicted triglyceride levels and endometriosis risk: Mendelian randomization with exploratory multi-omics analyses.PloS one · 2026Article
- Nursing-led education and its impact on knowledge, self-care practices, and pain intensity in women with endometriosis.Frontiers in public health · 2026Article
- Immune dysregulation in endometriosis: the T cell perspective.Frontiers in immunology · 2026Review
- A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of Linustedastat (OG-6219) in Women with Moderate to Severe Endometriosis-Related Pain.International journal of women's health · 2026Article
- Bidirectional Mendelian Randomization and Single‑Cell RNA Sequencing Reveal an NK Cell-Mediated Causal Link Between Endometriosis and Endometrial Cancer.International journal of women's health · 2026Article
- Endometriosis treatment pathways in the largest private health insurance in Brazil: A real-world data study.PloS one · 2026Article
- The Diagnostic Performance of Transvaginal Ultrasound for Posterior Compartment Endometriosis Compared to Laparoscopic and Histopathological Findings: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- ESHRE's key research priorities in infertility: maximizing impact on science, people and society†.Human reproduction (Oxford, England) · 2025Article
- Analysis of diagnostic apoptosis-related biomarkers and immune cell infiltration characteristics in endometriosis by integrating bioinformatics and machine learning.Scientific reports · 2025Article
- The impact of reproductive health needs on women's employment: a qualitative insight into managing endometriosis and work.BMC women's health · 2025Article
- IL-24 producing regulatory T and B lymphocytes in endometriosis.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is a chronic inflammatory disease that can have serious physical and emotional consequences for patients in terms of pain, quality of life, and infertility. Despite affecting about 10% of women, the pathophysiology and economic impact of the disease are not fully understood. This study aimed to review and summarize research articles quantifying the direct and indirect costs of endometriosis in the context of current national and international treatment guidelines. A search including the terms 'endometriosis' AND 'costs' OR 'cost of illness' OR 'cost analysis' OR 'economic burden' was performed, focusing on studies published between January 2000 and May 2022. Total costs, costs of primary and secondary care, productivity losses, and indirect costs were reported. The medical costs of endometriosis were principally registered in secondary care settings, where surgery was the main cost driver. There was considerable variability of populations and study settings, with the overall direct medical cost range of endometriosis from US$1459 to US$20,239 (2022) per patient per year. An increasing trend has been reported in secondary care costs over time; however, not enough data were available at this time to evaluate inpatient and outpatient costs versus treatment strategies. Similarly, further research is required to evaluate the costs and potential savings associated with new therapies. Numerous studies have evaluated the indirect costs of endometriosis in recent years, finding costs between US$4572 and US$14,079 (2022). Currently, limited data are available on the economic burden of the disease at the patient level.
Indexed as
Identifiers
36344867What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.